Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Journal of Radiation Biology

• Publication date

  2005-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/09553000400029460PMID 15962764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02

  2004cited by this paper
• Sensitization of breast cancer cells to radiation by trastuzumab.

  2003cited by this paper
• Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.

  2003cited by this paper
• Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.

  2003cited by this paper
• Quantitative biomarker analysis of synovial gene expression by real-time PCR

  2003cited by this paper
• Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

  2003cited by this paper
• Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

  2003cited by this paper
• C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation.

  2003cited by this paper
• Androgen and the blocking of radiation‐induced sensitization to Fas‐mediated apoptosis through c‐jun induction in prostate cancer cells

  2003cited by this paper
• Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.

  2003cited by this paper
• Early prostate cancer: clinical decision-making.

  2003cited by this paper
• Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413

  2003cited by this paper
• Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

  2002cited by this paper
• Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor.

  2002influential reference
• 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

  2002cited by this paper
• Effect of geldanamycin on androgen receptor function and stability

  2002cited by this paper
• Absolute quantification of AMPA receptor subunit mRNAs in single hippocampal neurons

  2001cited by this paper
• Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

  2001cited by this paper
• Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression

  2001cited by this paper
• Lack of prostate cancer radiosensitization by androgen deprivation.

  2001cited by this paper
• Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

  2001influential reference
• Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.

  2000cited by this paper
• HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

  2000cited by this paper
• Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

  2000cited by this paper
• Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

  2000cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

  1997cited by this paper
• Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system.

  1997cited by this paper
• Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats.

  1996influential reference
• Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.

  1995influential reference

• Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity

  2025cites this paper
• Radicicol - A multifaceted natural product with promising anticancer and anti-inflammatory activities: Insights into its mechanisms and therapeutic perspectives.

  2025cites this paper
• Radiation-induced effect of heat shock protein and potential clinical application

  2024cites this paper
• Advances in the role of heat shock protein 90 in prostate cancer

  2022cites this paper
• Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression

  2022cites this paper
• Natural resorcylic acid lactones: a chemical biology approach for anticancer activity.

  2021cites this paper
• Immunohistochemical expression of interlukin10 (IL10) and heat shock protein-90 (HSP-90) in prostatic carcinoma

  2020cites this paper
• Retraction Retracted: Apoptosis and Molecular Targeting Therapy in Cancer

  2020cites this paper
• Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

  2019cites this paper
• TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression

  2019cites this paper
• Chemical radiosensitizers: the Journal history

  2019cites this paper
• Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells

  2017cites this paper
• PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.

  2017influential citation
• C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro

  2017cites this paper
• The effect of heat shock factor 1 (HSF-1) and heat shock proteins Hsp70 and Hsp27 on radiosensitivity and immunogenicity

  2016cites this paper
• C0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity

  2016cites this paper
• Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.

  2015cites this paper
• Link between obesity and cancer: role of triglyceride/free fatty acid cycling.

  2014cites this paper
• Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening

  2014cites this paper
• MicroRNA Expression Profiling Altered by Variant Dosage of Radiation Exposure

  2014cites this paper
• High-throughput screening system to identify small molecules that induce internalization and degradation of HER2.

  2014cites this paper
• Down-regulation of Heat Shock Protein HSP90ab1 in Radiation-damaged Lung Cells other than Mast Cells

  2014cites this paper
• Apoptosis and Molecular Targeting Therapy in Cancer

  2014cites this paper
• Targeting heat shock protein 90 for malaria.

  2013cites this paper
• Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers

  2013cites this paper
• Targeting heat shock proteins in prostate cancer.

  2013cites this paper
• Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies

  2012cites this paper
• Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

  2012cites this paper
• B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.

  2012cites this paper
• Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia

  2012cites this paper
• Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

  2011cites this paper
• Inhibitors of heat shock protein 90 activity: A novel class of tumor radiosensitizers

  2011cites this paper
• Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

  2010cites this paper
• Hsp90: A Drug Target?

  2010cites this paper
• Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells.

  2010cites this paper
• Genomic Evaluation and Management of Prostate Cancer

  2010cites this paper
• Hsp90 inhibitors as promising agents for radiotherapy

  2010cites this paper
• Molecular targets for tumor radiosensitization.

  2009cites this paper
• Liposomal Encapsulation of Deguelin: Evidence for Enhanced Antitumor Activity in Tobacco Carcinogen–Induced and Oncogenic K-ras–Induced Lung Tumorigenesis

  2009cites this paper
• Heat Shock Protein 90 as a Drug Target: Some Like It Hot

  2009cites this paper
• An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo

  2009cites this paper
• Androgen Receptor Coregulators and Their Role in Prostate Cancer

  2009cites this paper
• CHAPERONE EXPRESSION AND EFFECTS OF ITS INHIBITION ON BREAST CANCER SENSITIZATION

  2009cites this paper
• Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.

  2008cites this paper
• Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells

  2008cites this paper
• Inhibition of Hsp 90 : AMultitarget Approach to Radiosensitization

  2007cites this paper
• Inhibition of Hsp90: A Multitarget Approach to Radiosensitization

  2007cites this paper
• Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs.

  2007cites this paper
• P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.

  2006cites this paper
• Inhibition of hsp90 compromises the DNA damage response to radiation.

  2006cites this paper
• IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

  2006cites this paper
• The HSP90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase.

  2006cites this paper
• New insights into prostate cancer biology.

  2006cites this paper
• ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.

  2005cites this paper
• ErbB 3 Expression Predicts Tumor Cell Radiosensitization Induced by Hsp 90 Inhibition

  2005cites this paper
• P 53-dependent radiosensitizing effects of Hsp 90 inhibitor 17-Allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines

  year unknowncites this paper